Azobenzene-incorporated Polymersomes for Control of Targeted Drug Delivery to Triple-Negative Breast Cancer

Introduction Results Conclusion Cont. Triple-negative breast cancer (TNBC) is a very aggressive form of breast cancer. It accounts for 15%-20% of breast cancer cases.1 Patients with TNBC have the worst prognosis. Their prognosis is caused by Hypoxia which is a result of poor angiogenesis.2 The most common treatment is Doxorubicin (Dox) but when used alone, can often diminish the patient’s quality of life.3 Using polymersomes, which are small nanovesicles, Dox can reach the hypoxic area directly without any systemic damage.4 This study will focus on using polymersomes with different hypoxic linkers, which should theoretically release the contents in the hypoxic area at differing rates based on their specific linkers. Additionally, this study will target the higher expression of receptor SLC7A11, which is important in cancer survival, by incorporating the drug Sulfasalazine.5